title: Emerging role of resveratrol in the treatment of severe acute pancreatitis.
abstract: Severe acute pancreatitis (SAP) develops in 15-20% of patients with acute pancreatitis. The management of SAP is a challenging task owing to the fact that it can lead to morbid conditions like multiple organ failure and systemic inflammatory response syndrome, if left untreated. Resveratrol, a drug used in Chinese traditional medicine has shown potential to treat many symptoms of SAP due to its multiple physiological actions. It possesses anti-inflammatory and anti-oxidative properties, both of which are essential in SAP. NF-kappaB activation is a major source of pro-inflammatory mediators in SAP. Administration of resveratrol can inhibit NF-kappaB activity as well as reduce the concentrations of TNF-alpha, IL-6 and IL-1. It can also scavenge reactive oxygen species that are capable of extensive tissue damage. Furthermore, resveratrol also exhibits anti-apoptotic properties via regulation of apoptotic mediators such as Bax, Bcl-2, and caspase-3. It also plays a role in calcium regulation and alleviates SAP-induced histopathological distortions in the pancreas. These multi-faceted results support the use of resveratrol in SAP and mandate the need for extensive research on this molecule.
authors.affiliation: Department of Surgery, First Affiliated Hospital of Xi'an, Jiaotong University Xi'an 710061, China.
authors.forename: Rajiv Kumar
authors.initials: RK
authors.lastname: Jha
authors.forename: Qingyong
authors.initials: Q
authors.lastname: Ma
authors.forename: Huanchen
authors.initials: H
authors.lastname: Sha
authors.forename: Muna
authors.initials: M
authors.lastname: Palikhe
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3 / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D019283:Pancreatitis, Acute Necrotizing / Q000188:drug therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D016207:Cytokines; D007375:Interleukin-1; D015850:Interleukin-6; D016328:NF-kappa B; D019253:Proto-Oncogene Proteins c-bcl-2; D017382:Reactive Oxygen Species; D013267:Stilbenes; D014409:Tumor Necrosis Factor-alpha; D051028:bcl-2-Associated X Protein; D053148:Caspase 3; D000077185:Resveratrol